JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Home・Aktien・Editas Medicine Inc

Editas Medicine Inc

Geschlossen

BrancheGesundheitswesen

2.91 -9.06

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.87

Max

2.95

Schlüsselkennzahlen
By Trading Economics
Einkommen	19M -5.6M
Verkäufe	17M 25M
EPS	-0.06
Gewinnspanne	-22.715
Angestellte	87
EBITDA	17M -5.3M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+144.67% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	11. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	123M 349M
Vorheriger Eröffnungskurs	11.97
Vorheriger Schlusskurs	2.91

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.33 / 1.54 Unterstützung & Widerstand

Editas Medicine Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Apr. 2026, 21:14 UTC

Wichtige Nachrichtenereignisse

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26. Apr. 2026, 21:14 UTC

Wichtige Nachrichtenereignisse

Week Ahead for FX, Bonds: Major Central Bank -2-

24. Apr. 2026, 19:19 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek Group Rejects EQT's Revised Offer

26. Apr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26. Apr. 2026, 23:44 UTC

Ergebnisse

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26. Apr. 2026, 23:44 UTC

Ergebnisse

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26. Apr. 2026, 23:36 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Falls Amid Dollar's Strength -- Market Talk

26. Apr. 2026, 23:33 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26. Apr. 2026, 05:12 UTC

Ergebnisse

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24. Apr. 2026, 23:37 UTC

Akquisitionen, Fusionen, Übernahmen

Scoring the Cook Era -- Barrons.com

24. Apr. 2026, 20:51 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Financial Services Roundup: Market Talk

24. Apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24. Apr. 2026, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 20:09 UTC

Ergebnisse

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24. Apr. 2026, 19:48 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24. Apr. 2026, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24. Apr. 2026, 19:25 UTC

Akquisitionen, Fusionen, Übernahmen

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24. Apr. 2026, 19:22 UTC

Ergebnisse

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24. Apr. 2026, 19:06 UTC

Ergebnisse

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24. Apr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24. Apr. 2026, 18:30 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24. Apr. 2026, 18:28 UTC

Akquisitionen, Fusionen, Übernahmen

Intertek Rejects Revised EQT Offer

24. Apr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24. Apr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24. Apr. 2026, 17:42 UTC

Ergebnisse

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24. Apr. 2026, 17:28 UTC

Ergebnisse

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Peer-Vergleich

Kursveränderung

Editas Medicine Inc Prognose

Kursziel

By TipRanks

144.67% Vorteil

12-Monats-Prognose

Durchschnitt 7.12 USD 144.67%

Hoch 15 USD

Tief 4 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Editas Medicine Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Editas Medicine Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.33 / 1.54Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.